Cargando…

Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritranspant Setting: A Case Report

Patient: Male, 37 Final Diagnosis: Chronic HCV-infection • hepatic decompensation Symptoms: Esophageal varices • portal-hypertensive gastropathy • splenomegaly • recurrent ascitic decompensation • hepatorenal syndrome • hepatic encephalopathy Medication: — Clinical Procedure: Liver transplantation •...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seifert, Leon Louis, Heinzow, Hauke, Kabar, Iyad, Christensen, Stefan, Hüsing, Anna, Schmidt, Hartmut H.-J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999016/ https://www.ncbi.nlm.nih.gov/pubmed/27554644 http://dx.doi.org/10.12659/AJCR.895839

Ejemplares similares

Hepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant Medicine
por: Hüsing, Anna, et al.
Publicado: (2015)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

Pictorial Representation of Illness and Self Measure (PRISM): A Novel Visual Instrument to Quantify Suffering in Liver Cirrhosis Patients and Liver Transplant Recipients
por: Kabar, Iyad, et al.
Publicado: (2018)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
por: Duerr, Michael, et al.
Publicado: (2019)

Chronic liver disease promotes lesions of the colorectal adenoma-carcinoma sequence, independent of liver cirrhosis
por: Troschel, Amelie S., et al.
Publicado: (2019)

Single-operator cholangioscopy for biliary complications in liver transplant recipients
por: Hüsing-Kabar, Anna, et al.
Publicado: (2017)

Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
por: Ashraf, Taha, et al.
Publicado: (2017)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
por: Hassuna, Noha Anwar, et al.
Publicado: (2022)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin
por: Poordad, Fred, et al.
Publicado: (2017)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
por: Sacco, Rodolfo, et al.
Publicado: (2020)

Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis
por: Chan, Huan-Tee, et al.
Publicado: (2021)

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
por: Shabani, M., et al.
Publicado: (2021)

Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature
por: Mirabella, Michele, et al.
Publicado: (2018)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats
por: Ibrahim, Mohamed A., et al.
Publicado: (2018)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
por: Luetkemeyer, Anne F., et al.
Publicado: (2016)

Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort
por: Lacombe, Karine, et al.
Publicado: (2017)

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
por: Joharji, Hala, et al.
Publicado: (2022)

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
por: de Medeiros, Lucas Pereira Jorge, et al.
Publicado: (2018)

Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019)

Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi
por: Butt, Nazish, et al.
Publicado: (2021)

The ameliorating role of sofosbuvir and daclatasvir on thioacetamide-induced kidney injury in adult albino rats
por: Moustafa, Ahmed H., et al.
Publicado: (2023)

Portal Hypertensive Polyposis in Advanced Liver Cirrhosis: The Unknown Entity?
por: Kara, David, et al.
Publicado: (2018)

Acute allograft rejection in liver transplant recipients: Incidence, risk factors, treatment success, and impact on graft failure
por: Dogan, Nurettin, et al.
Publicado: (2018)

Endoscopic Radiofrequency Ablation Prolongs Survival of Patients with Unresectable Hilar Cholangiocellular Carcinoma - A Case-Control Study
por: Bokemeyer, Arne, et al.
Publicado: (2019)

Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation
por: Bürger, Christin, et al.
Publicado: (2019)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Vitamin A Plasma Levels in COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
por: Tepasse, Phil-Robin, et al.
Publicado: (2021)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
por: Hassan, Amro M, et al.
Publicado: (2018)

Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection
por: Xue, Yan, et al.
Publicado: (2017)

Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy
por: El-Shabrawi, Mortada HF, et al.
Publicado: (2019)

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
por: Sokhela, Simiso, et al.
Publicado: (2022)

Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Publicado: (2016)

Enhanced monitoring and detection of recent genotype 3 hepatitis E virus infection through urine antigen testing
por: Stahl, Yannick, et al.
Publicado: (2023)

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
por: Poordad, Fred, et al.
Publicado: (2016)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]
Publicado: (2019)

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
por: Pellicelli, Adriano, et al.
Publicado: (2020)

End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir
por: Rahman, Attiya S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6b7ql6gg5gjfbunh55crnddj9t